- Home
- AVK vs PACB Comparison
AVK vs PACB Comparison
Compare AVK & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVK
- PACB
- Stock Information
- Founded
- AVK 2003
- PACB 2000
- Country
- AVK United States
- PACB United States
- Employees
- AVK N/A
- PACB N/A
- Industry
- AVK Trusts Except Educational Religious and Charitable
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- AVK Finance
- PACB Industrials
- Exchange
- AVK Nasdaq
- PACB Nasdaq
- Market Cap
- AVK 411.0M
- PACB 364.2M
- IPO Year
- AVK N/A
- PACB 2010
- Fundamental
- Price
- AVK $11.49
- PACB $1.13
- Analyst Decision
- AVK
- PACB Buy
- Analyst Count
- AVK 0
- PACB 13
- Target Price
- AVK N/A
- PACB $2.46
- AVG Volume (30 Days)
- AVK 112.9K
- PACB 8.3M
- Earning Date
- AVK 01-01-0001
- PACB 05-08-2025
- Dividend Yield
- AVK 11.85%
- PACB N/A
- EPS Growth
- AVK N/A
- PACB N/A
- EPS
- AVK N/A
- PACB N/A
- Revenue
- AVK N/A
- PACB $154,014,000.00
- Revenue This Year
- AVK N/A
- PACB $7.15
- Revenue Next Year
- AVK N/A
- PACB $26.20
- P/E Ratio
- AVK N/A
- PACB N/A
- Revenue Growth
- AVK N/A
- PACB N/A
- 52 Week Low
- AVK $9.24
- PACB $1.08
- 52 Week High
- AVK $12.16
- PACB $3.70
- Technical
- Relative Strength Index (RSI)
- AVK 37.10
- PACB 35.91
- Support Level
- AVK $11.38
- PACB $1.08
- Resistance Level
- AVK $11.89
- PACB $1.36
- Average True Range (ATR)
- AVK 0.14
- PACB 0.09
- MACD
- AVK 0.01
- PACB -0.00
- Stochastic Oscillator
- AVK 21.57
- PACB 17.24
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.